Stock info Sanofi-Aventis | Filter  Basic-Info

Stock: Sanofi-Aventis (Paris main group), ISIN: FR0000120578

Last Price 87.71 Max Price 104.62
Min Price 83.65 1 Year return -0.47
Avg. Target 106.14 Expected Return 21.02 %
Sector Health Care Subsector Pharmaceuticals
Sell 1 Rating Star full 12x12Star full 12x12Star full 12x12Star half 12x12
Hold 2 Concensus Cons sellCons holdCons buy
Buy 4
Annual report 2012

Sanofi-Aventis is a French pharmaceutical company active on a worldwide scale. Sanofi-Aventis develops and produces medicines. Sanofi-Aventis is one of the world’s largest pharmaceutical companies. The company employs around 30,000 people. Sanofi-Aventis’ stocks are traded on the Euronext Paris and the company is a component of the CAC40-index (ISIN: FR0000120578/ Mnemo: SAN).

Loading...

Contact info:Street: 54, rue La Boétie Zip Code: 75008 PariCity: Paris Country: FrancePhone: 33 (0)1 53 77 4Website: www.sanofi-aventis.fr

Sector Review Sanofi-Aventis

Loading...
Year Turnover Total sector Market share
2019 37,631 615,634 6.11 %
2020 37,369 638,070 5.86 %
2021 39,175 727,968 5.38 %
2022 45,389 787,273 5.77 %
2023 0 0 0.00 %

Advice Sanofi-Aventis

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
December 10, 2023 Jefferies & Co. Sanofi-Aventis Buy 115.00 23.73 %
November 05, 2023 JP Morgan Sanofi-Aventis Buy 92.00 4.66 %
November 05, 2023 Morgan Stanley Sanofi-Aventis Buy 98.00 10.50 %
November 05, 2023 Deutsche Bank Sanofi-Aventis Sell 80.00 -9.64 %
August 29, 2023 Citigroup Sanofi-Aventis Buy 138.00 36.44 %
July 14, 2023 HSBC Sanofi-Aventis Buy 120.00 26.91 %
May 23, 2023 UBS Sanofi-Aventis Hold 100.00 12.29 %
March 28, 2023 Barclays Sanofi-Aventis Hold 115.00 23.73 %
October 21, 2023 Deutsche Bank Sanofi-Aventis Sell 90.00 2.54 %
May 06, 2023 Morgan Stanley Sanofi-Aventis Buy 100.00 12.29 %
May 03, 2023 Deutsche Bank Sanofi-Aventis Sell
March 26, 2023 UBS Sanofi-Aventis Hold 93.00 5.69 %
March 26, 2023 Berenberg Sanofi-Aventis Hold 105.00 16.47 %
February 09, 2023 JP Morgan Sanofi-Aventis Buy 105.00 18.30 %
January 22, 2023 Credit Suisse Sanofi-Aventis Buy 114.00 17.23 %
January 05, 2023 Jefferies & Co. Sanofi-Aventis Buy 120.00 23.35 %
December 29, 2022 Barclays Sanofi-Aventis Hold 85.00 -5.11 %
December 19, 2022 Goldman Sachs Sanofi-Aventis Buy 134.00 35.72 %
December 14, 2022 Morgan Stanley Sanofi-Aventis Buy 95.00 9.34 %
December 01, 2022 Beleggers Belangen Sanofi-Aventis Hold
October 31, 2022 JP Morgan Sanofi-Aventis Buy 115.00 13.08 %
October 31, 2022 Deutsche Bank Sanofi-Aventis Hold 85.00 -17.60 %
September 15, 2022 Credit Suisse Sanofi-Aventis Buy 106.00 3.94 %
September 14, 2022 Berenberg Sanofi-Aventis Hold 91.00 -11.89 %
September 08, 2022 Jefferies & Co. Sanofi-Aventis Buy 110.00 10.35 %
August 30, 2022 Stifel Sanofi-Aventis Buy 105.00 5.08 %
August 14, 2022 Deutsche Bank Sanofi-Aventis Hold 90.00 -7.86 %
July 31, 2022 Deutsche Bank Sanofi-Aventis Sell 90.00 -5.51 %
June 21, 2022 Deutsche Bank Sanofi-Aventis Sell 85.00 -10.89 %
June 21, 2022 UBS Sanofi-Aventis Hold 119.00 20.79 %
April 27, 2022 Barclays Sanofi-Aventis Hold 105.00 2.08 %
April 26, 2022 Cowen and Company Sanofi-Aventis Buy 113.00 9.01 %
April 25, 2022 Morgan Stanley Sanofi-Aventis Hold 112.00 8.14 %
March 03, 2022 Stifel Sanofi-Aventis Buy 120.00 26.38 %
January 26, 2022 Liberum Sanofi-Aventis Buy 109.00 18.00 %
December 15, 2021 Jefferies & Co. Sanofi-Aventis Buy 120.00 26.23 %
November 29, 2021 Citigroup Sanofi-Aventis Buy 118.00 26.04 %
November 01, 2021 HSBC Sanofi-Aventis Buy 100.00 17.71 %
October 14, 2021 JP Morgan Sanofi-Aventis Buy 105.00 22.09 %
October 03, 2021 JP Morgan Sanofi-Aventis Buy 100.00 22.16 %



News Sanofi-Aventis

Sanofi-Aventis now in top highest dividend yields in France

Huge dividend Sanofi-Aventis Investors in Sanofi-Aventis can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the French market. Per share the analysts are expecting a dividend...

Sanofi and GlaxoSmithKline granted Indian approval for COVID-19 vaccine trial

Indian regulators have cleared a late-stage clinical trial for the experimental COVID-19 vaccine developed by Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK). In May, the two companies started the enrollment in a Phase 3 trial for the adjuvanted recombinant-protein...

Analysts expect over 2021 rising revenue Sanofi-Aventis, quite high dividend

Tomorrow the French Sanofi-Aventis will report its past quarters results. Over the current book year the total revenue will be 37.56 billion euros (consensus estimates). This is slightly more than 2020's revenue of 37.37 billion euros. Historical revenues and...

Sanofi to build new facility in Canada to boost influenza vaccine supply

Sanofi (NASDAQ:SNY) announces an investment of more than €600 million in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone...

Sanofi to buy Kymab for $1.45B

Sanofi will acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel...

Annual reports Sanofi-Aventis

2017 2018 2019 2020 2021

Profile Sanofi-Aventis

Sanofi-Aventis

(FR0000120578)/ SAN

The past year yielded positive returns for Sanofi-Aventis investors

Over the last 12 months, that were loss-making period for the investors in Sanofi-Aventis, the stock lost around 3 percent. Over the period 2011-2016 the stock rose a massive 37,06 percent. Sanofi-Aventis's revenues between 2011 and 2015 were relatively steady and moved between 35,96 billion euros and 34,86 billion euros. During 2011 and 2015 Sanofi-Aventis's net results were very volatile and fluctuated between 4,86 billion euros and 4,53 billion euros.

Sanofi-Aventis's head office is located in Paris . Sanofi-Aventis mainly operates in the pharmaceutical sector. The global pharmaceutical companies gained over the past 10 years on average 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The French company paid out dividends in the past 5 years. On average Sanofi-Aventis's dividend yield over the past 5 years was around 14 percent annually. Over the period 2011-2015 Sanofi-Aventis raised it's dividends per share each year. So because of the yearly raised dividends per share Sanofi-Aventis is a kind of dividend aristocrat.

Sanofi-Aventis' balance mostly consists of equity

At the end of 2015 the pharmaceutical company's balance sheet equaled 102,32 billion euros. Of the total balance sheet 44,27 billion euros (43,27 percent) was financed by debt. At the end of 2016 the French company was traded with a price/earnings-ratio of around 17. So investors paid 17 times the company's 2015's EPS. We could say that based on it's price/earnings-ratio and dividend yield the French stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 101,32 billion euros. At the end of 2015 the French company had around 1,31 billion stocks listed on the exchanges.

All Sanofi-Aventis's financial reports are available here. More information about Sanofi-Aventis can be found it's website. .


Results Sanofi-Aventis

Results
2015
2016
2017
2018
2019
2020
Revenue
34,861
34,708
36,204
35,677
37,631
37,369
Costs
30,569
30,004
27,792
31,371
34,877
25,075
Profit
4,292
4,704
8,412
4,306
2,754
12,294
Margin of profit
12.31
13.55
23.23
12.07
7.32
32.90
ROI
7.39
8.17
14.49
7.31
4.66
19.48

Balance Sanofi-Aventis

Balance
2015
2016
2017
2018
2019
2020
Equity
58,049
57,552
58,070
58,876
59,056
63,106
Debt
44,272
47,127
41,743
52,532
53,574
51,307
Total assets
102,321
104,679
99,813
111,408
112,630
114,413
Solvency
56.73
54.98
58.18
52.85
52.43
55.16
Cash
9,259
10,304
10,315
7,124
9,853
14,815
Cashflow
8,897
7,853
7,379
5,547
7,715
7,418
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.20
0.17
0.18
0.11
0.14
0.14

Details Sanofi-Aventis

Details
2016
2017
2018
2019
2020
Price
78.19
76.50
71.48
75.27
89.15
Eps
3.63
6.64
3.43
2.19
9.76
Price/earnings-ratio
21.54
11.52
20.84
34.37
8.99
Dividend
2.96
3.03
3.07
3.15
3.20
Dividend %
3.79 %
3.96 %
4.29 %
4.18 %
3.65 %
Payout %
0.82
0.46
0.90
1.44
0.33
Book value
45.25
46.31
47.27
47.10
50.46
Market to book
0.58
0.61
0.66
0.63
0.58
Cashflow per stock
6.17
5.89
4.45
6.15
5.93
Stocks
1,272
1,254
1,245
1,254
1,251
Market Cap
99.452.85
95.919.23
89.024.77
94.375.78
109.698.02

Dividend Sanofi-Aventis


Price info Sanofi-Aventis

Date
Price
22 Mar 2024
87.71
18 Mar 2024
88.00
15 Mar 2024
88.21
12 Mar 2024
88.34
11 Mar 2024
87.69
09 Mar 2024
87.69
07 Mar 2024
87.12
01 Mar 2024
87.89
29 Feb 2024
88.84
27 Feb 2024
89.28
22 Feb 2024
87.37
21 Feb 2024
87.13
20 Feb 2024
86.22
15 Feb 2024
85.73
14 Feb 2024
85.69
13 Feb 2024
86.07
09 Feb 2024
85.79
08 Feb 2024
85.79
07 Feb 2024
87.23
06 Feb 2024
87.40
05 Feb 2024
87.57
01 Feb 2024
93.36
31 Jan 2024
93.36
30 Jan 2024
92.67
27 Jan 2024
92.08
25 Jan 2024
92.55
24 Jan 2024
92.56
23 Jan 2024
94.20
16 Jan 2024
94.36
11 Jan 2024
94.85